Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor opened Phase 2 Study.

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG: tesevatinib

Sponsor

Kadmon Corporation, LLC